Baudax Bio (BXRX) - Channelchek Takeaway Series - The J.P.Morgan Healthcare Conference

A brief corporate overview from Baudax Bio CEO Gerri Henwood, followed by a Q&A with Noble Capital Markets Senior Research Analyst Greg Aurand.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on innovative products for hospital and related settings. The Company has a pipeline of innovative pharmaceutical assets including two clinical-stage, novel neuromuscular blocking (NMBs) agents, one in a Phase II study and an additional unique NMB in a dose escalation Phase I study, as well as a proprietary chemical reversal agent specific to these NMBs. Baudax Bio has received approval for and marketed ANJESO®, the first and only 24-hour, intravenous (IV) COX-2 preferential non-opioid, non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. For more information, please visit www.baudaxbio.com.

https://www.channelchek.com/company/bxrx

Скачать видео